Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

van Wyk AC, Lal P, J Ogunbiyi O, Kyokunda L, Hobenu F, Dial C, et al. Multinational, Multicenter Evaluation of Prostate Cancer Tissue in Sub-Saharan Africa: Challenges and Opportunities. JCO Glob Oncol. 2024;10:e2300403.

Stenzl A, Armstrong AJ, Sboner A, Ghith J, Serfass L, Bland CS, et al. Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology. Eur Urol Focus. 2024;10(6):1011-1018.

Hoellwarth JS, Reif TJ, Mori S, Kang R, Magro CM. Horrifying Basal Cell Carcinoma Presenting as Progressive Pyoderma Gangrenosum: Case Report. Case Rep Oncol. 2024;17(1):298-304.

Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, et al. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncol. 2024;10(6):718-725.

Yang HS. Machine Learning for Sepsis Prediction: Prospects and Challenges. Clin Chem. 2024;70(3):465-467.

Li Y, Deng K, Kaner J, Geyer JT, Ouseph M, Fang F, et al. Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements. Pathobiology. 2024;91(1):76-88.

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.

Southwell N, Manzo O, Bacman S, Zhao D, Sayles NM, Dash J, et al. High fat diet ameliorates mitochondrial cardiomyopathy in CHCHD10 mutant mice. EMBO Mol Med. 2024;16(6):1352-1378.

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.